Skip to main content

Table 2 Circulating levels of oestradiol, follicle-stimulating hormone and luteinizing hormone at baseline and after 12 months, and change from baseline to 12 months by treatment group

From: Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]

 

Isoflavone group (n= 56)

Placebo (n = 61)a

 
 

Baseline

12 months

Change

Baseline

12 months

Change

P for changeb

Oestradiol (pmol/l)

22.6 ± 12.2

36.6 ± 65.0

14.0 ± 64.7

22.6 ± 13.3

21.6 ± 9.0

-0.9 ± 11.5

0.49

FSH (IU/l)

76.2 ± 21.5

72.0 ± 23.5

-4.2 ± 12.9

77.6 ± 25.1

74.5 ± 23.9

-2.9 ± 13.0

0.83

LH (IU/l)

43.9 ± 15.4

39.9 ± 14.6

-4.0 ± 11.7

45.5 ± 16.0

41.2 ± 12.0

-4.2 ± 9.2

0.71

  1. Values are expressed as means ± standard deviation. aFor change in FSH, n = 60. b P value for difference between treatment groups for change. FSH, follicle-stimulating hormone; LH, luteinizing hormone.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us